Management of immunotherapy toxicities in older adults

被引：28

作者：

Bhandari, Shruti ^{[1
]}

Gill, Amitoj S. ^{[1
]}

Perez, Cesar A. ^{[2
]}

Jain, Dharamvir ^{[3
]}

机构：

[1] Univ Louisville, Sch Med, James Graham Brown Canc Ctr, Div Hematol & Med Oncol, Louisville, KY 40292 USA

[2] Sylvester Comprehens Canc Ctr, Div Med Oncol, Miami, FL USA

[3] Norton Canc Inst, 315 East Broadway,4th Floor, Louisville, KY 40202 USA

来源：

SEMINARS IN ONCOLOGY | 2018年 / 45卷 / 04期

关键词：

Older adults; Immune checkpoint inhibitors; Immune-related adverse events; CANCER-IMMUNOTHERAPY; NIVOLUMAB; AGE; MELANOMA; AUTOANTIBODIES; PEMBROLIZUMAB; PREVALENCE; IPILIMUMAB; BLOCKADE; EFFICACY;

D O I：

10.1053/j.seminoncol.2018.09.001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Advanced age is a risk factor for cancer and is attributed to dysregulation of the immune system. Historically, treatment of advanced cancer has primarily involved systemic chemotherapy that is associated with high treatment related toxicity especially in older adults. Immune checkpoint inhibitors (ICIs) provide an exciting treatment option for older adults in terms of efficacy and safety as compared to systemic chemotherapy. Given the pace of approval of ICIs for multiple cancers, there is an increase in both the use of las and the associated immune-related adverse events. In this article, we address how to approach immunotherapy related toxicities in older adults given the availability of limited data. (C) 2018 Elsevier Inc. All rights reserved.

引用

页码：226 / 231

页数：6

共 52 条

[1] Dendritic cells in human aging [J].

Agrawal, Anshu ;

Agrawal, Sudhanshu ;

Gupta, Sudhir .

EXPERIMENTAL GERONTOLOGY, 2007, 42 (05) :421-426

[2] Impact of aging in cancer immunotherapy The importance of using accurate preclinical models [J].

Bouchlaka, Myriam N. ;

Murphy, William J. .

ONCOIMMUNOLOGY, 2013, 2 (12)

[3] Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy [J].

Bouchlaka, Myriam N. ;

Sckisel, Gail D. ;

Chen, Mingyi ;

Mirsoian, Annie ;

Zamora, Anthony E. ;

Maverakis, Emanual ;

Wilkins, Danice E. C. ;

Alderson, Kory L. ;

Hsiao, Hui-Hua ;

Weiss, Jonathan M. ;

Monjazeb, Arta M. ;

Hesdorffer, Charles ;

Ferrucci, Luigi ;

Longo, Dan L. ;

Blazar, Bruce R. ;

Wiltrout, Robert H. ;

Redelman, Doug ;

Taub, Dennis D. ;

Murphy, William J. .

JOURNAL OF EXPERIMENTAL MEDICINE, 2013, 210 (11) :2223-2237

[4] Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination [J].

Boutros, Celine ;

Tarhini, Ahmad ;

Routier, Emilie ;

Lambotte, Olivier ;

Ladurie, Francois Leroy ;

Carbonnel, Franck ;

Izzeddine, Hassane ;

Marabelle, Aurelien ;

Champiat, Stephane ;

Berdelou, Armandine ;

Lanoy, Emilie ;

Texier, Matthieu ;

Libenciuc, Cristina ;

Eggermont, Alexander M. M. ;

Soria, Jean-Charles ;

Mateus, Christine ;

Robert, Caroline .

NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (08) :473-486

[5] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[6] Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline [J].

Brahmer, Julie R. ;

Lacchetti, Christina ;

Schneider, Bryan J. ;

Atkins, Michael B. ;

Brassil, Kelly J. ;

Caterino, Jeffrey M. ;

Chau, Ian ;

Ernstoff, Marc S. ;

Gardner, Jennifer M. ;

Ginex, Pamela ;

Hallmeyer, Sigrun ;

Chakrabarty, Jennifer Holter ;

Leighl, Natasha B. ;

Mammen, Jennifer S. ;

McDermott, David F. ;

Naing, Aung ;

Nastoupil, Loretta J. ;

Phillips, Tanyanika ;

Porter, Laura D. ;

Puzanov, Igor ;

Reichner, Cristina A. ;

Santomasso, Bianca D. ;

Seigel, Carole ;

Spira, Alexander ;

Suarez-Almazor, Maria E. ;

Wang, Yinghong ;

Weber, Jeffrey S. ;

Wolchok, Jedd D. ;

Thompson, John A. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) :1714-+

[7]

Candore G, 2002, ARCH GERONTOL GERIAT, P75

[8] Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper [J].

Champiat, S. ;

Lambotte, O. ;

Barreau, E. ;

Belkhir, R. ;

Berdelou, A. ;

Carbonnel, F. ;

Cauquil, C. ;

Chanson, P. ;

Collins, M. ;

Durrbach, A. ;

Ederhy, S. ;

Feuillet, S. ;

Francois, H. ;

Lazarovici, J. ;

Le Pavec, J. ;

De Martin, E. ;

Mateus, C. ;

Michot, J. -M. ;

Samuel, D. ;

Soria, J. -C. ;

Robert, C. ;

Eggermont, A. ;

Marabelle, A. .

ANNALS OF ONCOLOGY, 2016, 27 (04) :559-574

[9] Molecular Pathways: Next-Generation Immunotherapy-Inhibiting Programmed Death-Ligand 1 and Programmed Death-1 [J].

Chen, Daniel S. ;

Irving, Bryan A. ;

Hodi, F. Stephen .

CLINICAL CANCER RESEARCH, 2012, 18 (24) :6580-6587

[10] T cell subset-specific susceptibility to aging [J].

Czesnikiewicz-Guzik, Marta ;

Lee, Won-Woo ;

Cui, Dapeng ;

Hiruma, Yuko ;

Lamar, David L. ;

Yang, Zhi-Zhang ;

Ouslander, Joseph G. ;

Weyand, Cornelia M. ;

Goronzy, Joerg J. .

CLINICAL IMMUNOLOGY, 2008, 127 (01) :107-118

← 1 2 3 4 5 6 →